Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 19:2022:5132135.
doi: 10.1155/2022/5132135. eCollection 2022.

Predictive Value of MRI with Serum Lectin-Reactive Alpha-Fetoprotein for Liver Cancer Recurrence after Percutaneous Radiofrequency Ablation

Guangfeng Zhang  1 , Yongxing Yun  1 , Chunming Lin  1 , Huafeng Li  2
Affiliations

Predictive Value of MRI with Serum Lectin-Reactive Alpha-Fetoprotein for Liver Cancer Recurrence after Percutaneous Radiofrequency Ablation

Guangfeng Zhang et al. Evid Based Complement Alternat Med. .

Retraction in

Abstract

Objective: To explore the predictive value of magnetic resonance imaging (MRI) with serum lectin-reactive alpha-fetoprotein (AFP-L3) for liver cancer recurrence after percutaneous radiofrequency ablation (RFA).

Methods: This study included 94 liver cancer patients admitted for RFA treatment and 82 healthy subjects. MRI was performed to record the apparent diffusion coefficient (ADC). The serum concentrations of AFP-L3 were quantified in all participants. The correlation of the AFP-L3 serum level and ADC value with clinical efficacy following RFA was analyzed. Moreover, the prognostic factors affecting liver cancer recurrence were analyzed, as well as the predictive effect of the ADC value and AFP-L3 on liver cancer recurrence.

Results: The serum AFP-L3 level was higher in liver cancer patients than the healthy controls with a lower ADC value. Besides, the patients with tumor residuals had lower ADC values and higher serum AFP-L3 levels than those with complete ablated tumor. The combined detection of the ADC value and serum AFP-L3 level had a sensitivity of 87.50% and a specificity of 87.18% for diagnosing complete ablation after RFA treatment. The number of tumor nodules, tumor diameter, AFP, AFP-L3, and the presence of liver cirrhosis are all independent risk factors for liver cancer recurrence within one year. Meanwhile, the combined detection of the ADC value and serum AFP-L3 level had a good predictive effect on liver cancer recurrence with the sensitivity of 92.86% and a specificity of 69.62%.

Conclusion: The ADC values combined with serum AFP-L3 detection had good predictive effects on complete ablation and recurrence of liver cancer after RFA treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Comparison of the serum level of AFP and AFP-L3, and ADC values between the liver cancer group and the healthy control group. Note: (a-b) comparison of AFP (a) and AFP-L3 (b) levels between the liver cancer group and the healthy control group. (c) comparison of ADC values between the liver cancer group and the healthy control group. ∗P < 0.05.
Figure 2
Figure 2
Correlation of the ADC value and AFP-L3 with the efficacy of RFA in liver cancer patients. Note: (a-b) comparison of the serum level of AFP-L3 (a) and ADC values (b) between liver cancer patients with complete ablation and those with residual tumor, ∗P < 0.05. (c-d) ROC curve of the serum level of AFP-L3 (c) and ADC values (d) in diagnosing tumor residue after RFA treatment in liver cancer patients; (e) ROC curve of the AFP-L3 serum level combined with the ADC value for the diagnosis of tumor residue after RFA treatment.
Figure 3
Figure 3
Relationship between the ADC value, AFP-L3, and prognostic recurrence. Note: (a-b) comparison of the serum level of AFP-L3 (a) and ADC values (b) between nonrelapsed patients and relapsed patients. (c-d) ROC curve of the AFP-L3 serum level (c) and ADC values (d) for the diagnosis of liver cancer recurrence. (e) ROC curve of the AFP-L3 serum level combined with the ADC value for the diagnosis of liver cancer recurrence.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Speciale A., Muscara C., Molonia M. S., Cristani M., Cimino F., Saija A. Recent advances in glycyrrhetinic acid-functionalized biomaterials for liver cancer-targeting therapy. Molecules . 2022;27(6) doi: 10.3390/molecules27061775.1775 - DOI - PMC - PubMed
    1. Anwanwan D., Singh S. K., Singh S., Saikam V., Singh R. Challenges in liver cancer and possible treatment approaches. Reviews on Cancer . 2020;1873(1) doi: 10.1016/j.bbcan.2019.188314.188314 - DOI - PMC - PubMed
    1. Li X., Ramadori P., Pfister D., Seehawer M., Zender L., Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nature Reviews Cancer . 2021;21(9):541–557. doi: 10.1038/s41568-021-00383-9. - DOI - PubMed
    1. Sun J. H., Luo Q., Liu L. L., Song G. B. Liver cancer stem cell markers: progression and therapeutic implications. World Journal of Gastroenterology . 2016;22(13):3547–3557. doi: 10.3748/wjg.v22.i13.3547. - DOI - PMC - PubMed
    1. Winters A. C., Shaltiel T., Sarpel U., Branch A. D. Liver cancer has a distinctive profile in black patients: current screening guidelines may be inadequate. Hepatology Communications . 2022;6(1):8–11. doi: 10.1002/hep4.1771. - DOI - PMC - PubMed

Publication types

LinkOut - more resources